Levels of soluble Fas/APO-1 in patients with Behçet's disease. by Hamzaoui, K et al.
Levels of soluble Fas/APO-1 in







1Immunohistology Laboratory, Medicine University
of Tunis, Pavillon VI, 9 rue Dr Z. Essafi 1007 Tunis,
Tunisia; 
2Department of Respiratory Diseases, Pav II,
Ariana; 
3Department of Rheumatology, Marsa
Hospital, Tunisia
CACorresponding Author
Fax: (+216) 1 569 427
THE aim of this study was to quantify soluble Fas/APO-
1 (sFas/APO-1) protein in the serum of patients with
Behçet’s  disease  (BD)  in  active  and  inactive  stages,
compared with patients with systemic lupus erythe-
matosus (SLE) and patients with rheumatoid arthritis
(RA). Soluble Fas/APO-1 was quantified using a sand-
wich enzyme-linked immunosorbent assay. Increased
serum sFas/APO-1 levels were observed in active BD,
compared  with  inactive  BD,  RA  patients  and  SLE
patients.  Increased  serum  sFas/APO-1  levels  were
correlated with the presence of neurologic manifesta-
tions  or  pulmonary  involvement  in  active  BD.  In
conclusion, increased levels of sFas/APO-1 occurred
frequently  and  exclusively  in  active  BD  patients.
Preliminary evidence suggested that elevated levels of
sFas/APO-1 are associated with the clinical stage and
clinical manifestations in BD.
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Introduction
Apoptosis or programmed cell death is an important
mechanism that maintains cellular homeostasis.1,2The
programmed  cell  death  involves  the  interaction
between surface and soluble molecules: bcl-2, Fas and
Fas ligand.3 Fas/APO-1/CD95 is a membrane receptor
that  signals  apoptosis  in  activated  mature  lympho-
cytes.4 Recent studies have demonstrated the impor-
tance of this receptor in triggering activation-induced
T cell death by apoptosis.5
Fas/APO-1  receptor  molecule  which  lacked  the
transmembrane segment, resulted in a soluble form of
Fas/Apo-1 (sFas/Apo-1).6These studies suggested that
elevated serum levels of sFas/Apo-1 receptor might
provide  a  mechanism  for  downregulating  program-
med  cell  death,  which  could  be  important  in  the
pathogenesis  of  several  diseases:  autoimmune  and
viral diseases.
Behçet’s disease (BD) is characterized by a number
of T  lymphocyte  abnormalities,7 overproduction  of
IgM and IgG immunoglobulins,8 production of autoan-
tibodies and presence of immature CD4-CD8-T cells.9
In BD and in patients suffering from immunovasculitis,
sarcoidosis, multiple sclerosis, SLE, increased numbers
of activated immunocytes may serve as parameters in
the evaluation of the clinical activity of autoimmun-
ity.10 We have recently observed abundant expression
of  bcl-2  protein  in T  lymphocytes  from  peripheral
blood and inflammatory sites: bronchoalveolar lavage
(BAL)  and  cerebrospinal  fluid  (CSF)  of  active  BD
patients,11 which may represent an attempt to main-
tain an activated lymphocyte population against the
aetiological antigen or a primary abnormality  of an
autoimmune process. For these reasons, much interest
has focused on the possible role of a defective Fas/
APO-1 pathway in BD.  To examine the role of sFas/APO-
1 in BD, we quantified this protein in the serum of
patients with active and inactive BD.
Materials and Methods
Patients
Serum was obtained from normal controls (n = 20)
and from patients with BD (n = 50). Thirty patients
were in active stage of BD and 20 patients were in
inactive stage (mean age 46 years, range 27–42 years).
They were characterized according to the criteria of
the  International  Study  Group  of  Behçet’s  Disease
(ISG).12 They had recurrent oral and genital ulcera-
tions, and uveitis, associated to one or more other
clinical  manifestations. Ten  of  them  were  suffering
from  pulmonary  manifestations  (a  chronic  cough
associated to interstitial shadows on the chest roent-
genogram,  pulmonary  aneurysm). Another  five  BD
patients  had  neurologic  manifestations  (menin-
goencephalitis, seizures, papilloedema, cranial nerve
palsy).13 Serum  was  obtained  from  23  randomly
selected patients with systemic lupus erythematosus
(SLE), and from 20 patients with rheumatoid arthritis
(RA)  (according  to  the  criteria  of  the  American
Rheumatism Association for RA, and the ACR revised
criteria for SLE).14,15
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Soluble  Fas/APO-1  levels  were  measured utilizing  a
sandwich  enzyme-linked  immunosorbent  assay.16
Microtitre wells were coated with 1m g/ml anti-Fas/
APO-1 Mo Ab (rabbit polyclonal anti-Fas/APO-1 anti-
body) and blocked with 2%  bovine serum albumin in
PBS. Test sera were added neat and at serial dilutions
and incubated for 3h. The wells were washed and
sequentially incubated with rabbit anti-Fas/APO-1 IgG
followed by peroxidase-conjugated mouse anti-rabbit
IgG (absorbed for cross-reactivity against human IgG;
Dianova, Hamburg, Germany) and substrate solution
(0.1%  OPD in 0.05M citric acid, 0.1M Na2 HPO4). The
reaction  was  terminated  at  10min  and  the  optical
density  at  492nm  read  in  an  ELISA  reader  (Sanofi
Pasteur, France). The detection limit of the assay was
2pg/ml, the interassay variation was < 5%, and intra-
assay variation was < 25% .16
Statistics
Statistical  significance  was  assessed  by  the  Mann–
Whitney U test for non-parametric data. Differences
were considered significant if P £  0.05.
Results
The ELISA values were expressed as mean ± SD, in 20
BD patients in inactive stage, in 30 active BD patients,
in  23  SLE  patients  and in 20  RA patients  (Fig.  1).
Soluble  Fas/APO-1  obtained  from  the  20  normal
controls  were  (2.13  ±  0.93ng/ml).  Patients  with
active  BD  exhibited  increased  sFas/APO-1  (4.04  ±
1.3ng/ml). Values more than 2SD above the normal
control mean (corresponding to 4ng/ml) were con-
sidered positive. By this criterion, the most important
values of sFas/APO-1 were observed in 13 active BD
patients characterized by the presence of vasculitis
(5.60 ± 0.94ng/ml). Inactive BD had lower values of
sFas/APO-1 (2.76 ± 0.89ng/ml) than patients in active
stage  (P <  0.01).  SLE  patients  and  RA  patients
exhibited increased sFas/APO-1 respectively in 1/23
patients and in 2/20 patients. The values of sFas/APO-
1  were  in the  same  levels  in SLE  patients  (2.12  ±
0.98ng/ml) and RA patients (2.47 ± 1.16ng/ml).
The increased expression of sFas/APO-1 in active
BD,  was  highly  correlated to  clincal  manifestations
(Fig. 2): patients with pulmonary manifestations and
neurologic involvement.
Discussion
The aetiology of BD is unknown yet, and our aim is to
understand the pathways of tissues injury. The sites of
disease activity are characterized by prominent and
persistent inflammatory infiltrates. We questioned the
defect  of  apoptosis,  enabling  cytotoxic  cells
survival.
We investigated possible apoptotic abnormalities in
patients with BD in peripheral blood lymphocytes, in
sera and in inflammatory sites. We did observe high
levels of bcl-2 protein on CD3+ T cells.11 In this work,
we looked for a possible dysregulation in Fas/APO-1
expression in patients with BD, depending upon the
clinical stage. Levels of sFas/APO-1 from BD patients
were compared with patients suffering from autoim-
mune disease: SLE or RA.
In  our  report  1/23  SLE  patients  and  2/20  RA
patients  exhibited  an  increased  sFas/APO-1  level.
Increased  sFas/APO-1  expression  was  previously
reported  in  1/27  SLE  patients  and  3/10  JRA
patients.16,17 High  levels  of  sFas/APO-1  were  also
reported  in  patients  with  leukaemias  and  lympho-
mas.16 It has been suggested that increased levels of
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FIG.  1.  Serum  levels  of  soluble  Fas/APO-1  (s-APO-1)  in
Behçet’s disease with active and inactive stage. Soluble Fas/
APO-1,  expressed  in  ng/ml,  was  quantified  by  sandwich
enzyme-linked immunosorbent assay using anti-Fas/APO-1
antibody  for  detection.  Values  more  than  2SD  above  the
mean in normal controls (shown by the horizontal line) were
considered positive. Patients with active BD expressed high
levels of sFas/APO-1, compared with patients with systemic
lupus  erythematosus  (SLE)  and  patients  with  rheumatoid
arthritis (RA). There was no significant difference between
sFas/APO-1 levels in the control subjects and patients with
SLE or RA.sFas/APO-1  may  be  responsible  in part  for  autoim-
munity in SLE.6 Our report about SLE is in accordance
with the results of Knipping;16 elevated levels of sFas/
APO-1  were  depicted  only  in  a  minority  of  SLE
patients. We think that sFas/APO-1 is not an important
primary event in the induction of human autoimmune
disease.
In the present study elevated levels of sFas/APO-1
were detected in severe forms of BD. An explanation
for the presence of sFas/APO-1 in BD serum could be
proteolytic cleavage of the membrane form of Fas/
APO-1. The detection of soluble form of Fas/APO-1 is
an important finding which may explain the ‘escape’
of Fas/APO-1+ cells from detection by the Fas/APO-1
ligand.6 Soluble  sFas/APO-1  can  protect  cells  from
undergoing apoptosis by preventing the binding of
the Fas ligand to the target cells.
The increased expression of sFas/APO-1 in active
BD (13/30 patients) with confirmed neurological and
pulmonary manifestation, could be correlated to the
severity  of  the  disease.  In  eight  BD  patients  with
pulmonary manifestations, and in five patients with
neurologic involvement, vasculitis was confirmed by
physicians.
Our  laboratory  results  showed  that  BD  patients
with  vasculitis,  have  particular  biologic  findings:
accumulation of cytotoxic TCRg d + cells at the sites of
inflammation,7 high level of endothelin expression,13
high  autoantibodies  against  endothelial  cells
(AECA),18 increased  oxygen  radical  production,19
high  levels  of  cICAM-1,20 and  CD11/CD18  bearing
lymphocytes in cerebrospinal fluid.21 Most of these
biological and immunological parameters have been
described in various autoimmune and vasculitis condi-
tions.  The  present  report  showed  an  additional
finding:  increased  expression  of  sFas/APO-1.  This
result was specific to active BD with vasculitis, and
not to an autoimmune disorder.
Apoptosis  is  a  critical  mechanism  by  which  the
immune system maintains tolerance to self-antigen. In
BD, taking in account the ubiquitous increased levels
of bcl-2 and sFas/APO-1 may be important in inhibi-
tion  of  apoptosis  of  resting  cells,  and  sFas/APO-1
production by activated cells may lead to excessive
immune responsiveness. The sFas/APO-1 is capable of
inhibiting Fas-mediated apoptosis of reacting lympho-
cytes to self antigen in vivo. Soluble Fas/APO-1 can
protect cells from undergoing apoptosis by prevent-
ing the binding of the Fas ligand to the target cells.
Our  finding  in  BD  suggest  a  crucial  role  for  this
molecule. Therapies such as plasmapheresis that may
remove soluble Fas/APO-1 from sera of severe BD may
probably  restore  normal  apoptosis  and  reduce  an
eventual  agression.22,23 In  conclusion,  our  results
suggest that  sFas/APO-1 may be a useful  marker in
evaluating  the  extent  of  injury  in  BD  vasculitis
condition.
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